GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts

Cbio launches first-in-human trial for groundbreaking cervical cancer therapy

China’s NMPA approves Zydus-licensed anaemia drug Desidustat

Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients

Wanbury bags key Brazil nod, eyes market expansion

Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA

Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema

Veristat expands global trial & regulatory services as Chinese drugmakers push overseas

The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals

Aster DM bags overwhelming shareholder backing for merger with Quality Care

The endorsement follows overwhelming support for the share swap preceding the merger,

Co-Diagnostics bags key Japanese patent, bolstering global push for rapid PCR testing

The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

Marks significant milestone for breakthrough biologic to treat rare blood cancers